HONG KONG – For the past several years, biopharma firms around the globe have been urged to develop a strategy for moving into China, and with good reason. China's pharmaceutical market value is expected to grow from $123 billion in 2017 to $160 billion by 2022, according to management consulting firm L.E.K. Consulting.